SCOHIA PHARMA, Inc.

Company Company

Company information Board members Corporate Name and Logo

Business Business

Business process Business strategy Management team Scientific advisor

Pipeline Pipeline

Pipeline TOP Direct renin inhibitor | SCO-272 Enteropeptidase inhibitor | SCO-792 GPR40 full agonist | SCO-267 GLP-1R/GIPR dual agonist | SCO-094 SSTR5 antagonist | SCO-240 IP6K inhibitor | SCO-006 NRF2 activator | SCO-116

Pipeline TOP Direct renin inhibitor | SCO-272 Enteropeptidase inhibitor | SCO-792 GPR40 full agonist | SCO-267 GLP-1R/GIPR dual agonist | SCO-094 SSTR5 antagonist | SCO-240 IP6K inhibitor | SCO-006 NRF2 activator | SCO-116

EN JP

News

Publication

2019.06.11

Publication regarding a preclinical study of SCO-267,a novel GPR40 agonist

Back All

Page Top

Publication regarding a preclinical study of SCO-267,a novel GPR40 agonist

We use cookies to improve your experience on our site.
Please accept the use of cookies to continue. Read more

ACCEPT

SCOHIA PHARMA, Inc.

Company

Company information
Board members
Corporate Name and Logo

Business

Business process
Business strategy
Management team
Scientific advisor

Pipeline

Pipeline TOP
Direct renin inhibitor | SCO-272
Enteropeptidase inhibitor | SCO-792
GPR40 full agonist | SCO-267
GLP-1R/GIPR dual agonist | SCO-094
SSTR5 antagonist | SCO-240
IP6K inhibitor | SCO-006
NRF2 activator | SCO-116

Terms of Use Privacy Policy

Copyright © 2019 SCOHIA PHARMA, Inc. All rights reserved.